Rational design of a protein-protein interaction inhibitor that activates Protein Tyrosine Phosphatase 1B.

Read full text Summarise with VIRAT
Authors: Avinash D. Londhe, Sophie Rizzo, Syed Husain Mustafa Rizvi, Reddy Sudheer Sagabala, Sanjukta Guha, Alexandre Bergeron, Reagan A. Costello, ChangHwan Lee, Nilesh K. Banavali, Damien Thévenin, Benoît Boivin
Cited by: 0
References: 63

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Reversible inactivation of protein tyrosine phosphatases by reactive oxygen species (ROS) is essential to the maintenance of phosphorylation of growth factor receptors. An important outcome of the inactivation of protein tyrosine phosphatase 1B (PTP1B) by ROS involves the conformational change of its phosphotyrosine binding loop which adopts a solvent-exposed position in its oxidized form. We previously demonstrated that the regulatory protein 14-3-3ζ interacts with the phosphotyrosine binding loop of the oxidized form of PTP1B. Using a rational approach, we developed a unique protein-protein interaction (PPI) inhibitor peptide derived from the phosphotyrosine binding loop of PTP1B designed to disrupt this interaction between PTP1B and the 14-3-3ζ-complex. Exploiting this cell-penetrating PPI inhibitor peptide, we show decreased association between PTP1B and the 14-3-3ζ-complex in cells treated with epidermal growth factor (EGF). We also demonstrate that preventing the association of this 14-3-3ζ-complex to PTP1B deters oxidation and inactivation of PTP1B following EGF receptor (EGFR) activation and generation of ROS. Treating cells with our PPI inhibitor decreases EGFR phosphorylation on PTP1B-specific sites. Furthermore, treating EGFR-driven epidermal cancer cells with our PPI inhibitor also significantly inhibits colony formation and cell viability, consistent with increased activation of PTP1B. These data highlight the ability of PTP1B to downregulate critical signaling pathways in cancer when activated using peptide drugs such as our PPI inhibitor. We anticipate that preventing or destabilizing the reversible oxidation of other members of the protein tyrosine phosphatase superfamily using PPI inhibitors may offer a foundation for a broad therapeutic approach to rectify dysregulated signaling pathways in vivo .

Fields of Study & Subjects

Protein Tyrosine Phosphatases Protein Kinase Regulation and GTPase Signaling Redox biology and oxidative stress

Publication details

Journal / source
Redox Biology
Pages
104483–104483
Publication date
1 November 2026
Language
EN